

# CITATION REPORT

List of articles citing

## Time course of the interaction between tadalafil and nitrates

DOI: 10.1016/j.jacc.2003.09.023

Journal of the American College of Cardiology, 2003,  
42, 1855-60.

**Source:** <https://exaly.com/paper-pdf/35360518/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 152 | Emerging oral drugs for erectile dysfunction. <b>2004</b> , 9, 179-189  |      | 4         |
| 151 | Tadalafil: A Comprehensive Update. <b>2004</b> , 2, 225-246   |      |           |
| 150 | Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil. <b>2004</b> , 17, 239-250  |      | 1         |
| 149 | Sildenafil and cardiovascular events [Drug interactions]. <b>2004</b> , 143-149   |      |           |
| 148 | Role of the cardiologist: Clinical aspects of managing erectile dysfunction. <b>2004</b> , 27, 3-7  |      | 7         |
| 147 | Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. <b>2004</b> , 27, 120-5   |      | 22        |
| 146 | Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. <b>2004</b> , 172, 1935-40   |      | 133       |
| 145 | Time course of the interaction between tadalafil and nitrates. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 2150; author reply 2150-1   | 15.1 | 3         |
| 144 | Reply. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 2150-2151   | 15.1 | 2         |
| 143 | Reply. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 2149-2150   | 15.1 |           |
| 142 | P-235: Blood pressure goal attainment: comparative efficacy of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. <b>2004</b> , 17, S118-S119   |      |           |
| 141 | Interaction between nitrates and tadalafil. <b>2004</b> , 17, S119  |      |           |
| 140 | The decrease in urinary albumin excretion after irbesartan treatment in normotensive diabetes type 1 patients with incipient nephropathy is related to blood pressure, and not to changes in soluble cytokines and growth factors. <b>2004</b> , 17, S119 |      |           |
| 139 | Menopause as a clinical indicator for the treatment for hypertension with nifedipine gits as monotherapy. the star study. <b>2004</b> , 17, S119-S120   |      |           |
| 138 | Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. <i>Circulation</i> , <b>2004</b> , 110, 3149-55  | 16.7 | 143       |
| 137 | Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2004</b> , 1, 185-196   |      |           |
| 136 | Beta-adrenoceptor antagonists and antianginal drugs. <b>2005</b> , 217-222  |      |           |

|     |  |     |
|-----|--|-----|
| 135 | Phosphodiesterase type 5 inhibitors for erectile dysfunction. <b>2005</b> , 96, 257-80   | 153 |
| 134 | The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. <b>2005</b> , 60, 459-68      | 19  |
| 133 | Erectile dysfunction in patients with coronary artery disease. <b>2005</b> , 17, 209-15  | 19  |
| 132 | A case of erectile dysfunction and risk factors for coronary artery disease. <b>2005</b> , 17 Suppl 1, S7-S11  | 3   |
| 131 | From aspiration to achievement: assessment and noninvasive treatment of erectile dysfunction in aging men. <b>2005</b> , 53, 119-30                  | 14  |
| 130 | Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. <b>2005</b> , 47, 214-20; discussion 220-2 | 188 |
| 129 | Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). <b>2005</b> , 96, 313-21  | 216 |
| 128 | Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. <b>2005</b> , 96, 37M-41M   | 36  |
| 127 | Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. <b>2005</b> , 96, 42M-46M      | 63  |
| 126 | Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). <b>2005</b> , 96, 85M-93M   | 99  |
| 125 | Nitric oxide and penile erectile function. <b>2005</b> , 106, 233-66   | 163 |
| 124 | Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. <b>2005</b> , 23, 374-84  | 25  |
| 123 | Tadalafil: a clinical update. <b>2005</b> , 1, 203-214   | 3   |
| 122 | Tadalafil. <b>2005</b> , 85-107  |     |
| 121 | Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. <b>2005</b> , 2, 239-47   | 40  |
| 120 | Chronic stable angina. <b>2005</b> , 353, 1524; author reply 1524  | 1   |
| 119 | Sildenafil Citrate, the Classic PDE5 Inhibitor. <b>2005</b> , 65-83  | 4   |
| 118 | Oral Pharmacotherapy for Male Sexual Dysfunction. <b>2005</b> ,  |     |

|     |  |     |     |
|-----|--|-----|-----|
| 117 | Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. <b>2005</b> , 4, 531-40   |     | 18  |
| 116 | PDE-5 inhibitors: current status and future trends. <b>2005</b> , 32, 511-25, viii   |     | 25  |
| 115 | Chapter 1: The management of erectile dysfunction: an AUA update. <b>2005</b> , 174, 230-9   |     | 255 |
| 114 | Retrospective Evaluation of Sildenafil Citrate as a Therapy for Pulmonary Hypertension in Dogs. <b>2006</b> , 20, 1132-1135  |     | 77  |
| 113 | Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. <b>2006</b> , 316, 654-61  |     | 60  |
| 112 | Optimizing outcomes in the patient with acute decompensated heart failure. <b>2006</b> , 151, 571-9  |     | 21  |
| 111 | Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. <b>2006</b> , 67, 1199-204  |     | 54  |
| 110 | Erectile Dysfunction in the Patients with Cardiovascular Disease. <b>2006</b> , 47, 279  |     | 3   |
| 109 | . <b>2006</b> ,  |     | 21  |
| 108 | Oral Pharmacotherapy of Erectile Dysfunction. 75-93  |     | 5   |
| 107 | Factors associated with recent sildenafil (viagra) use among men who have sex with men in the United States. <b>2006</b> , 42, 95-100  |     | 27  |
| 106 | Phosphodiesterase-5 inhibitors and their hemodynamic effects. <b>2006</b> , 8, 345-51  |     | 23  |
| 105 | The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. <i>Journal of Sexual Medicine</i> , <b>2006</b> , 3, 28-36; discussion 36 | 1.1 | 230 |
| 104 | Cardiovascular effects of phosphodiesterase 5 inhibitors. <b>2006</b> , 12, 3485-94  |     | 45  |
| 103 | Erectile dysfunction and hypertension. <b>2007</b> , 19, 296-302   |     | 67  |
| 102 | Chronic sildenafil in men with diabetes and erectile dysfunction. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2007</b> , 3, 451-64                                  | 5.5 | 24  |
| 101 | A dramatic drop in blood pressure following prehospital GTN administration. <b>2007</b> , 24, 225-6  |     | 6   |
| 100 | Are nitrates safe in patients who use sildenafil? Maybe. <b>2007</b> , 35, 1988-90   |     | 5   |

|    |   |     |    |
|----|---|-----|----|
| 99 | Phosphodiesterase type 5 inhibitors: state of the therapeutic class. <b>2007</b> , 34, 507-15, vi   |     | 23 |
| 98 | Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. <b>2007</b> , 19, 281-95   |     | 33 |
| 97 | Pharmacologic Options for Treatment of Ischemic Disease. <b>2007</b> , 77-120   |     | 0  |
| 96 | [Novel indications for phosphodiesterase type 5 inhibitors]. <b>2007</b> , 102, 617-30  |     | 4  |
| 95 | Phosphodiesterase type 5 inhibitors and nitrates: Is concomitant use safe? Are there alternatives?. <b>2007</b> , 4, 59-63  |     |    |
| 94 | NHG-Standaard Erectiele disfunctie. <b>2008</b> , 51, 381-394   |     | 9  |
| 93 | Does sildenafil cause myocardial infarction or sudden cardiac death?. <b>2008</b> , 8, 1-7  |     | 18 |
| 92 | The use of phosphodiesterase 5 inhibitors with concomitant medications. <b>2008</b> , 31, 799-808   |     | 49 |
| 91 | The cardiovascular safety of tadalafil. <b>2008</b> , 7, 43-52  |     | 8  |
| 90 | Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction. <b>2008</b> , 4, 24-30                          |     | 9  |
| 89 | Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition. <b>2008</b> , 39, 323-328 |     | 4  |
| 88 | Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2008</b> , 5, 355-365            |     | 2  |
| 87 | Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complications. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 2074-84                 | 1.9 | 91 |
| 86 | Tadalafil in the treatment of erectile dysfunction. <b>2008</b> , 4, 1315-30  |     | 57 |
| 85 | Update on the Use of Phosphodiesterase Inhibitors in the Treatment of Erectile Dysfunction. <b>2009</b> , 2, 113-121  |     | 1  |
| 84 | Intravenous therapy for hypertensive emergencies, part 2. <b>2009</b> , 66, 1448-57   |     | 33 |
| 83 | Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. <b>2009</b> , 21, 149-57   |     | 12 |
| 82 | [Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil]. <b>2009</b> , 48, 1318, 1320-9                         |     | 7  |

|    |   |      |     |
|----|---|------|-----|
| 81 | Vardenafil: efficacy, tolerability and future directions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2009</b> , 5, 553-62   | 5.5  | 3   |
| 80 | Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors. <b>2009</b> , 3, 201-211   |      | 1   |
| 79 | Treatment of erectile dysfunction in the older diabetic patient. <b>2010</b> , 6, 9-29  |      |     |
| 78 | Erectile dysfunction as a complication of heart failure. <b>2010</b> , 7, 194-201   |      | 9   |
| 77 | Pharmacotherapy for erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 524-40   | 1.1  | 132 |
| 76 | Pharmacologic Interactions in the CICU. <b>2010</b> , 516-531   |      | 1   |
| 75 | A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. <b>2010</b> , 4, 159-71   |      | 23  |
| 74 | Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. <i>Circulation</i> , <b>2010</b> , 122, 88-95   | 16.7 | 78  |
| 73 | PDE5 inhibitors and their applications. <b>2010</b> , 17, 2564-87   |      | 21  |
| 72 | Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates. <b>2010</b> , 26, 1451-9   |      | 4   |
| 71 | Patient preparation and scanning techniques. <b>2010</b> , 48, 675-86   |      | 13  |
| 70 | Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrrolidinyloxyethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one (DA-8159) and nitroglycerin in rats. <b>2005</b> , 57, 1397-405 |      |     |
| 69 | Drug Interactions and Adventures in Polypharmacy. <b>2011</b> , 215-235   |      |     |
| 68 | The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. <b>2011</b> , 21, 820-8   |      | 12  |
| 67 | Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. <b>2011</b> , 33, 993-1004   |      | 27  |
| 66 | Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men. <b>2011</b> , 33, 1590-608  |      | 10  |
| 65 | A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 1341-1348   | 4    | 11  |
| 64 | Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i> , <b>2012</b> , 125, 1058-72   | 16.7 | 202 |

|    |   |      |      |
|----|---|------|------|
| 63 | Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 1481-94  | 4    | 15   |
| 62 | Tadalafil for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 747-55   | 4    | 13   |
| 61 | Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction. <b>2012</b> , 29, 771-81  |      | 8    |
| 60 | Sexual function in patients with chronic angina pectoris. <b>2013</b> , 111, 1671-6   |      | 6    |
| 59 | Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts. <b>2013</b> , 10, 26-35  |      | 14   |
| 58 | SOP conservative (medical and mechanical) treatment of erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 130-71   | 1.1  | 117  |
| 57 | Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs. <b>2013</b> , 190, 799-806   |      | 10   |
| 56 | Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. <b>2013</b> , 33, 639-49   |      | 16   |
| 55 | An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 1333-44   | 4    | 72   |
| 54 | Stable Angina. <b>2013</b> , 419-438  |      |      |
| 53 | Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations. <b>2014</b> , 7, 271-6  |      | 3    |
| 52 | Prescriber perceptions of a near real-time fax alert program for potential drug-drug interactions. <i>Journal of Managed Care Pharmacy</i> , <b>2014</b> , 20, 494-500a   |      | 2    |
| 51 | Management of erectile dysfunction in hypertension: Tips and tricks. <i>World Journal of Cardiology</i> , <b>2014</b> , 6, 908-15   | 2.1  | 36   |
| 50 | 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , <b>2014</b> , 130, e344-426   | 16.7 | 754  |
| 49 | 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , <b>2014</b> , 130, 2354-94                                   | 16.7 | 696  |
| 48 | 2014 AHA/ACC Guideline for the Management of Patients With NonST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, e139-e228 | 15.1 | 132  |
| 47 | 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, e139-e228                   | 15.1 | 1822 |
| 46 | Sexual activity and ischemic heart disease. <i>Current Cardiology Reports</i> , <b>2014</b> , 16, 445   | 4.2  | 15   |

|    |   |      |    |
|----|---|------|----|
| 45 | Survivorship: sexual dysfunction (male), version 1.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2014</b> , 12, 356-63                          | 7.3  | 5  |
| 44 | Ipertensione arteriosa: il ruolo dell'Internista. <i>Italian Journal of Medicine</i> , <b>2015</b> , 3, 1   | 0.5  |    |
| 43 | Erectile Dysfunction in Hypertension and Cardiovascular Disease. <b>2015</b> ,  |      | 2  |
| 42 | Nitrates, organic. <b>2016</b> , 192-202  |      |    |
| 41 | A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy. <i>Journal of Clinical Medicine</i> , <b>2016</b> , 5,   | 5.1  | 12 |
| 40 | Pharmacology of drugs used for the treatment of erectile dysfunction. <b>2016</b> , 48-55   |      | 0  |
| 39 | Non-ST Elevation Acute Coronary Syndromes: A Comprehensive Review. <i>Current Problems in Cardiology</i> , <b>2017</b> , 42, 266-305  | 17.1 | 9  |
| 38 | Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2017</b> , 15, 1140-1163   | 7.3  | 63 |
| 37 | Management of patients after primary percutaneous coronary intervention for myocardial infarction. <i>BMJ, The</i> , <b>2017</b> , 358, j3237                                   | 5.9  | 6  |
| 36 | Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2017</b> , 13, 183-192 | 5.5  | 19 |
| 35 | Non-ST-Segment Acute Coronary Syndromes. <i>Cardiology Clinics</i> , <b>2018</b> , 36, 37-52  | 2.5  | 16 |
| 34 | A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2018</b> , 23, 375-386     | 2.6  | 9  |
| 33 | Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats. <i>Pharmaceutics</i> , <b>2019</b> , 11,                                   | 6.4  | 3  |
| 32 | Tadalafil for the treatment of benign prostatic hyperplasia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 929-937   | 4    | 12 |
| 31 | Pharmacologic Interactions. <b>2019</b> , 432-445.e7  |      |    |
| 30 | Therapeutic Strategies for Erectile Dysfunction With Emphasis on Recent Approaches in Nanomedicine. <i>IEEE Transactions on Nanobioscience</i> , <b>2020</b> , 19, 11-24        | 3.4  | 1  |
| 29 | The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease. <i>Physiological Reports</i> , <b>2020</b> , 8, e14556         | 2.6  | 2  |
| 28 | Update of the position paper on arterial hypertension and erectile dysfunction. <i>Journal of Hypertension</i> , <b>2020</b> , 38, 1220-1234                                    | 1.9  | 9  |



|    |  |     |                |
|----|--|-----|----------------|
| 27 | Ficus plants in the Co-management of Hypertension and Erectile dysfunction. <i>Phytomedicine Plus</i> , <b>2021</b> , 1, 100096  |     | 1              |
| 26 | Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States. <i>Journal of Sexual Medicine</i> , <b>2021</b> , 18, 1511-1523 | 1.1 | 2              |
| 25 | Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. <b>2004</b> , 139-161   |     | 1              |
| 24 | Sexual function in hypertensive patients receiving treatment. <i>Vascular Health and Risk Management</i> , <b>2006</b> , 2, 447-55   | 4.4 | 3 <sup>1</sup> |
| 23 | Tadalafil: A Comprehensive Update. <b>2004</b> , 2, 225-246  |     | 1              |
| 22 | Beta-blocker administration protocol for prospectively ECG-triggered coronary CT angiography. <i>World Journal of Cardiology</i> , <b>2013</b> , 5, 453-8  | 2.1 | 20             |
| 21 | Erectile Dysfunction and the Heart. <b>2006</b> , 367-373  |     |                |
| 20 | Drugs Used to Treat Hypertension, Heart Failure, and Angina Pectoris. <b>2009</b> , 1-196  |     |                |
| 19 | Acute heart failure syndromes. <b>2009</b> , 47-70   |     |                |
| 18 | NHG-Standaard Erectiele disfunctie. <b>2009</b> , 1291-1313  |     |                |
| 17 | Nitrates and Newer Antianginals. <b>2009</b> , 38-58   |     |                |
| 16 | NHG-Standaard Erectiele disfunctie. <b>2011</b> , 1495-1517  |     |                |
| 15 | Principles of Sports Nutrition. <b>2014</b> , 46-89  |     |                |
| 14 | Sport for Individuals with an Impairment. <b>2014</b> , 30-45  |     |                |
| 13 | Basic Principles of the Princeton Recommendations. <b>2015</b> , 213-229   |     |                |
| 12 | Acute Heart Failure Syndromes. <b>2017</b> , 81-162  |     |                |
| 11 | Male Sexual Dysfunction in Systemic Sclerosis. <i>In Clinical Practice</i> , <b>2021</b> , 299-305   | 0   |                |
| 10 | Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?. <i>Current Vascular Pharmacology</i> , <b>2021</b> , 19, 301-312   | 3.3 | 2              |

|   |   |     |    |
|---|---|-----|----|
| 9 | Stable Angina. <b>2005</b> , 451-470  |     |    |
| 8 | Cardiac Issues Related to Erectile Dysfunction. <b>2006</b> , 61-75   |     |    |
| 7 | Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2004</b> , 1, 185-196   |     |    |
| 6 | Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction. <i>P and T</i> , <b>2013</b> , 38, 407-19  | 1.4 | 49 |
| 5 | Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease : A Case-Crossover Study.. <i>Annals of Internal Medicine</i> , <b>2022</b> , | 8   | 0  |
| 4 | Nitrates and newer antianginals. <b>2013</b> , 38-63  |     | 1  |
| 3 | Application of Modern Analytical Techniques for quantification of Tadalafil in Pharmaceutical and Biological Matrices: Future Prospectus.. <b>2022</b> , 19,  |     | 0  |
| 2 | Making Dentistry Even Safer: Understanding the Proper Choice and Use of Emergency Medications. <b>2019</b> , 47, 455-463  |     | 0  |
| 1 | Phosphodiesterase Type 5 Inhibitors and Oral Nitrates in Male Patients with Ischemic Heart Disease.   |     | 0  |